Tofacitinib ± NB-UVB in Vitiligo: Case Series and Open-Label Evidence
Key Takeaways Topical and oral tofacitinib show signals of repigmentation in case series/open studies, with best facial responses. NB-UVB appears […]
JAK inhibitor
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V1 and TRuE-V2 Phase 3 Results
Key Takeaways Two parallel phase 3 RCTs (TRuE-V1/V2) showed superiority vs vehicle on F-VASI at week 24, with continued gains
Tofacitinib in Vitiligo: Case Series and Open-Label Studies ± NB-UVB
Key Takeaways Tofacitinib (JAK1/3 inhibitor) has shown facial repigmentation in multiple case series; responses improve with concurrent light (NB-UVB or
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V2 Phase 3 Results
Key Takeaways TRuE-V2 confirmed facial repigmentation superiority of ruxolitinib 1.5% cream versus vehicle at ~24 weeks, mirroring TRuE-V1. Continued treatment
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V1 Phase 3 Results
Key Takeaways In TRuE-V1, topical ruxolitinib 1.5% cream showed clinically meaningful facial repigmentation versus vehicle by week 24, with continued